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OBJECTIVE—Comorbid depression is common in patients with type 1 and type 2 diabetes,
adverselyaffectingqualityoflife,diabetesoutcomes,andmortality.Depressioncanbeeffectively
treated with cognitive behavior therapy (CBT). The Internet is a new and attractive method for
delivering CBT intervention on a large scale at relatively low costs. This study evaluated the
effectivenessofWeb-basedCBTfordepressiontreatmentinadultswithtype1ortype2diabetes,
with minimal guidance.
RESEARCH DESIGN AND METHODS—A randomized controlled trial was conducted
in the Netherlands in 255 adult diabetic patients with elevated depressive symptoms. Primary
outcomes were depressive symptoms. Secondary outcomes were diabetes-speciﬁc emotional
distress and glycemic control. Assessments were at baseline, after treatment, and at the 1-month
follow-up.
RESULTS—The Web-basedCBT waseffective in reducingdepressive symptoms byintention-
to-treat analyses (P=0.04, d = 0.29; clinical improvement 41% vs. 24% P , 0.001) and by per-
protocol analyses (P , 0.001, d = 0.70; clinical improvement, 56% vs. 24% P , 0.001). The
intervention reduced diabetes-speciﬁc emotional distress (P = 0.03) but had no beneﬁcial effect
on glycemic control (P . 0.05).
CONCLUSIONS—Web-based CBT depression treatment is effective in reducing depressive
symptoms in adults with type 1 and type 2 diabetes. In addition, the intervention reduces di-
abetes-speciﬁc emotional distress in depressed patients.
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A
ffecting 10 to 20% of adult diabetic
patients, depression is a common
comorbid health problem among
people with type 1 or type 2 diabetes
(1). Comorbid depression in diabetes re-
sults in a lower quality of life, poorer gly-
cemic control, an increased risk of
developing diabetes-related complica-
tions, and higher mortality rates (2). De-
pression,therefore,needstoberegardeda
serious and common comorbidity in di-
abetes, negatively affecting both mental
and physical health.
In routine diabetes care, depression
remains untreated in at least 50% of the
patients (2). Undertreatment occurs
partly because patients are not inclined
to discuss their emotional problems
with their physician, and health care pro-
fessionals feel under-resourced and lack
the tools to refer or treat depression in
their diabetic patients (2).
A recent meta-analysis showed that
depression in people with diabetes can be
treated effectively with antidepressant
medication, psychotherapy, or combined
therapy, with possible beneﬁts on diabetes
outcomes(3).Ameta-analysisshowedthat
usingtheInternettodeliverpsychotherapy
is an effective treatment option for depres-
sion and could help to increase reach and
facilitate access to effective depression
treatment against relatively low costs (4).
Lewinsohn’sC o p i n gw i t hD e p r e s s i o n
course (CWD) is currently the most
studiedandproven effectivecognitivebe-
havioral therapy (CBT) treatment of de-
pression, and given its highly structured
character, is suitable for making a Web-
based version (5). The effectiveness of a
Web-basedversionofCWD—ColorYour
Life (CYL)—has been shown (6,7). Be-
cause CWD, and speciﬁcally CYL, is
highly structured, it requires adaptation
t os u b g r o u p so fp a t i e n t st h a ta r eb e i n g
addressed, such as those previously de-
veloped and tested in randomized con-
t r o l l e dt r i a l si ne l d e r l y ,y o u n gp e o p l e ,
and patients with chronic diseases (5).
Between 56 and 75% of depressed
patients with diabetes experience high
levels of emotional distress directly re-
lated to diabetes (8). Recent studies have
shown that the beneﬁcial effects of de-
pression treatment on glycemic control
are mediated by diabetes-related distress
(9,10). Health care providers have there-
fore been advised to address disease-
speciﬁce m o t i o n a ld i s t r e s st oi m p r o v e
the effectiveness of depression treatment
and to beneﬁt diabetes outcomes (9).
Therefore, in close collaboration with
the researchers who developed CYL, we
adapted this course to meet the needs of
diabetic patients, thus maximizing ac-
ceptability (11). This diabetes-sensitive
CYL (Diabetergestemd.nl, DG.nl) takes
into account the speciﬁc coping issues
diabetic patients are faced with related to
physical problems, the daily burden of self-
management, and the risk of long-term
complications. The need to adapt CWD to
diabetic patients was conﬁrmed by consult-
ingdiabeticpatients,professionals,andfrom
our own clinical experience (11).
The primary aim of this study was to
test the effectiveness of DG.nl in a ran-
domized controlled trial. We hypothe-
sized that depressive symptoms would
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ORIGINAL ARTICLEreduce signiﬁcantly more in the inter-
vention condition than in the control
condition. Additionally, we expected
beneﬁcial effects of the intervention on
diabetes-speciﬁce m o t i o n a ld i s t r e s sa n d
glycemic control.
RESEARCH DESIGN AND
METHODS—This study was approved
by the Medical Ethics Committee of the
VU University Medical Center.
Design overview
The effectiveness of the intervention was
tested in a randomized controlled trial,
and its design is described in more detail
elsewhere(12).Eligiblepatientswereran-
domly assigned to the Web-based inter-
vention or to a 12-week waiting list
control group. The assessments in the
intervention group were scheduled di-
rectly after participants completed or
had stopped the Web-based interven-
tion (postassessment), and at a 1 month
follow-up assessment (Fig. 1).
Setting and participants
Patients were recruited from July 2008
through September 2009 by advertise-
ments in various general and diabetes-
speciﬁc media. Patients could individu-
ally sign up for participation in the study
through an open access study Web site.
After having signed informed consent,
patients were invited to ﬁll out the base-
lineassessmentthroughapersonalonline
questionnaire, and they received a tele-
phone administered diagnostic interview.
To participate in the study, adult diabetic
patients were required to have a score of
$16 on the Centre for Epidemiological
Studies Depression scale (CES-D), have
an e-mail address, and access to the Inter-
net. Exclusion criteria were a history of
suicide attempt(s) or current suicidal ide-
ation, bipolar depression or psychotic
disorder, pregnancy, and recent loss of a
signiﬁcant other (,6m o n t h sa g o ) .
Randomization
Randomization by computer was used to
assign participants to the experimental or
control condition, at individual level.
Subjects were informed about the out-
comeofrandomizationbye-mail,directly
after the diagnostic interview. Blinding of
participants was not possible given the
Figure 1—Consolidated Standards of Reporting Trials (CONSORT) ﬂow diagram.
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blinded to whether patients were allo-
cated directly to the intervention or
gained access to the intervention at a later
stage, after the waitlist phase.
Interventions
Web-based CBT. A detailed description
of the intervention can be found else-
where (11).Inshort,participantsindivid-
ually went through eight consecutive
lessons that provided written and spoken
information and videos of depressed di-
abetic patients explaining how they
learned from the course. Coaches (certi-
ﬁed health psychologists) provided feed-
back on homework assignments #3
workingdays.Feedbackwastoalargede-
gree standardized and consisted of a con-
cise, constructive reply on the CBT
techniques,meanttohelppatientsunder-
stand and apply the CBT skills in daily
practice. In case homework was not re-
ceived, patients were sent reminders after
1 week and after 2 weeks. If no reply was
received #3 weeks, participants received
an e-mail stating we had to assume that
they were no longer interested in the in-
tervention, and were invited to ﬁlloutthe
postmeasurement. However, if still inter-
ested, they were invited to re-enter the
course.
Waiting list. Participantsallocatedtothe
waiting list control group completed
measurements 8 weeks (postassessment)
and 12 weeks after randomization
(1-month follow-up assessment). After
this 12-week waiting period, patients re-
ceived a password that allowed them to
log in to the Web-based intervention, if
they still had elevated depressive symp-
toms (CES-D $16).
Measurements
Baseline measures. Characteristics of
the study sample were self-reported as
part of the online baseline assessment:
sociodemographic data (age, gender,
marital state, level of education, and
current occupation), lifestyle (smoking,
alcoholuse),anddataondiabetes(typeof
diabetes, treatment regimen, anddiabetes
duration and diabetes complications),
BMI, and use of antidepressant medica-
tion.
The World Health Organization Com-
posite International Diagnostic Interview–
auto(WHOCIDI-auto)wasusedtodiagnose
depression and to exclude patients when
detecting bipolar disorder, psychotic fea-
tures, current suicidal ideation, or suicide
attempt(s) in the past. The WHO CIDI-
auto is a computerized, fully structured
diagnosticinterviewthatassessesdiagnos-
tic criteria of mental disorders according
to the Diagnostic and Statistical Manual of
Mental Disorders (DSM-IV) (13). Because
questionsandroutesarefullyspeciﬁed,no
clinicaljudgmentisrequired.Interviewers
were master students in clinical psychol-
ogy at the VU University in Amsterdam,
trained in the administration of the WHO
CIDI-auto by telephone. At the end of the
telephone interview, standardized feed-
back was given to the patient on the out-
come.
Outcomes
The main outcome was symptoms of
depression, assessed with the CES-D, a
widely used 20-item self-report instru-
ment. The CES-D has shown strong
criterion validity compared with struc-
tured diagnostic interviews (14). Re-
spondents are asked to indicate the
frequency with which they experienced
depressive symptoms in the preceding
week. Scores range from 0 to 60, with
scores of $16 representing a clinically
signiﬁcant level of depressive symptoms.
Secondary outcomes were diabetes-
speciﬁc emotional distress and glycemic
control. Diabetes-speciﬁc emotional dis-
tress was assessed with the Dutch version
of the Problem Areas in Diabetes (PAID)
scale, a widely used 20-item self-report
questionnaire (15). Items pertain to neg-
ative emotions related to living with di-
abetes, rated on a 5-point Likert scale,
ranging from 0 (“not a problem”)t o4
(“a serious problem”). Sum scores are
converted to a 0–100 scale. We used a
score of $40 as cutoff for high distress
(8,15).
As an indictor of glycemic control,
patients’ glycosylated hemoglobin (A1C,
reference range 4.3–6.1%) measured
closest to the date of premeasurement
and the 1-month follow-up was retrieved
from their treating physicians. Poor
glycemic control was deﬁned as A1C of
$8% (16).
Sample size calculation. The sample
size was calculated based on the expected
differenceindepressivesymptoms,which
was the primary outcome variable. Based
ona statisticalpowerof 0.80,with an aof
0.05, 100 subjects were required in each
group to be able to detect differences with
aneffectsizeof0.35(17).Withanexpected
30% study attrition, we determined the
study sample size needed randomization
of 286 participants.
Statistical analysis
Statistical analyses were completed with
SPSS 15.0 and Stata 10.0 software. Base-
line characteristics were compared for the
intervention and control group using
Student t tests, x
2 tests, and analyses of
variance to test whether randomization
had been successful. Two-sided tests
with the level of signiﬁcance established
at 0.05 were applied for all analyses.
Analyses were performed on both
intention-to-treat (ITT) principles and
per-protocol (PP) analyses. In PP analy-
ses, subjects who completed the full eight
lessons of DG.nl were compared with the
control group.
Longitudinal regression analyses
were performed using generalized esti-
mating equations. Interaction effects of
treatment (intervention versus control
group) 3 time (baseline, postassessment,
and at 1-month follow-up) were calcu-
lated to test whether developments over
time between intervention and control
groupdiffered.Becausevariabilitywasex-
pected in the duration of the course (con-
sidering our rules for dropping out of
the course, the duration of the course
could vary between 5 and 24 weeks), we
corrected for time between pre- and post-
treatment measurement in all analyses.
Furthermore, all analyses were corrected
for baseline depressive symptoms and for
use of self-reported pharmacologic and
psychologic treatment during the study.
Between-group effect sizes were cal-
culated using Cohen d, using the follow-
ing formula: d =M 1 2 M2 / spooled,i n
which spooled = ![(s1
2 + s2
2)/2 ] .
Effect sizes larger than d=0.8 were
considered to be large, d =0 . 5 –0.8 as
moderate, and d =0 . 2 –0.5 as small (18).
In addition, clinically signiﬁcant
change was determined, deﬁned as hav-
i n gr e c o v e r e da n ds h o w i n gs i g n i ﬁcant
improvement on the CES-D. Recovery
was deﬁned as having a score ,16 on the
CES-D(14).Improvementwasdetermined
following the suggestions of Jacobson and
Truax(19),calculatingareliablechange
index (RC) using the following formula:
RC =
x2-x1/Sdiff..P a t i e n t sw h ob o t hi m -
proved and recovered were considered
as being “clinically signiﬁcantly im-
proved.”
Learning from previous studies on
Web-based interventions, we expected
highstudyattritionrates(4). Nonrandom
study attrition may jeopardize ITT prin-
ciples and lead toward an overestimation
of effect sizes. Therefore, when establish-
ing nonrandom study attrition, missing
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tion by chained equations. In contrast to
otherimputationtechniques,thismethod
minimally alters variance of data, thus
providing the best estimates of missing
data, at least until 50% of missing data
(20). Consequently, all analyses could
be performed on complete data.
RESULTS
Randomization and study attrition
Of the 410 individuals who expressed
interest in our study, 255 patients were
eligible and randomized: 125 patients
were allocated to the intervention group
and 130 to the control group. Study
attrition for the full study sample was 82
(32%) for postassessment, 88 (35%) for
the 1-month follow-up assessment, and
was higher in the intervention group than
in the control group: 52 (42%) vs. 36
(28%; P=0.01). Study dropouts were
moreoftendiagnosedwithananxietydis-
order (49% vs. 31%, P , 0.01). Within
the control group, study dropouts
showed higher baselinedepression scores
of 31 6 8v s .2 76 7 for non dropouts
(P , 0.01; Fig. 1).
Regarding the intervention group,
study attrition was higher in noncomp-
letersofthecourseatthe1-monthfollow-
up (45 of 72, 63%) than in completers of
t h ec o u r s e( 7o f5 3 ,1 3 % ;P , 0.001).
Because study attrition was higher in the
intervention group (speciﬁcally in non-
completers of the course) relative to the
control group, study attrition was not
completely at random,justifying multiple
imputation (20).
Baseline characteristics
Baseline sociodemographic and clinical
characteristics of the study sample are
presented in Table 1. The intervention
and control groups did not signiﬁcantly
differ regarding demographic and clinical
characteristicsatbaseline.Thestudysam-
ple was 89% white (n=227), 61% female
(n=155),97% were moderatelyto highly
educated (n=247), and 55% (n=141)
were diagnosed with type 2 diabetes.
High levels of depressive symptoms
were conﬁrmed at baseline, with a mean
CES-D score of 28 6 7. Diabetes-speciﬁc
emotional distress was also high, with a
mean PAID score of 40 6 19. Mean A1C
was 7.4 6 1.3%, indicating relatively
well-controlled diabetes, with 27% hav-
ing an elevated level of A1C (.8.0%).
Seventy-ninepatients(31%)self-reported
one or more diabetes complication.
Change in depressive symptoms
Mean time between pre- and post-
treatment was 12 6 8 weeks for the inter-
vention group, comprising 14 6 9 weeks
in course completers and 11 6 7 weeks in
course noncompleters. Generalized esti-
mating equation analyses revealed a sig-
niﬁcant treatment multiplied by time
interaction effect on depressive symptoms
(CES-D;P,0.001).Fordepressivesymp-
tomsat1-monthfollow up,d= 0.29 (95%
CI 0.17–0.40).
Secondary outcomes
Asigniﬁcanttreatmenttimestimeeffect
w a sf o u n df o rP A I D( P , 0.001). No
signiﬁcant treatment effect was found
for A1C levels (P . 0.05). When patients
with elevated baseline A1C levels only
were examined, a signiﬁcant treatment
effect was still not found for A1C (P .
0.05).
Clinically signiﬁcant improvement
Compared with the control group, a
signiﬁcantly higher percentage of the
intervention group showed clinically
signiﬁcant improvement at postassess-
ment (37% vs. 19%, P , 0.001) and at
the 1-month follow-up (41% vs. 24%,
P , 0.001).
PP analyses
Of those randomized to the intervention
group, 53 (42%) completed the entire
eight-lesson course, 30 (24%) completed
no lesson at all, and 7 (6%) never logged
intothecourse.Otherparticipantsdropped
outequallydividedduringthecourse.The
53 completers and the 72 noncompleters
Table 1—Baseline sociodemographic and clinical characteristics of participants at baseline
Characteristics
All
patients
(n= 255)
CBT
participants
(n= 125)
Waiting list
control*
(n= 130)
Sociodemographics
Mean age, year 50 6 12 48 6 12 51 6 12
Women, n (%) 155 (61) 82 (66) 73 (56)
Caucasian, n (%) 227 (89) 110 (88) 117 (90)
Marital state–with partner, n (%) 199 (78) 99 (79) 100 (77)
Education level, n (%)
No formal qualiﬁcations 8 (4) 5 (5) 3 (3)
High school or lower/middle vocational
qualiﬁc a t i o n s 1 3 6( 5 3 ) 7 0( 5 6 ) 6 6( 5 1 )
College qualiﬁcations or more 111 (44) 50 (40) 61 (47)
Employed, n( % ) 1 2 6( 4 9 ) 6 4( 5 1 ) 6 2( 4 8 )
Lifestyle-related factors
Smoking, n ( % ) 4 5( 1 8 ) 2 3( 1 8 ) 2 2( 1 7 )
Mean alcohol consumption, units/week 6 6 75 6 77 6 8
Clinical diabetes proﬁle
Type 2 diabetes, n (%) 141 (55) 66 (53) 75 (58)
Insulin-treated type 2, n ( % ) 6 9( 4 9 ) 3 5( 5 3 ) 3 4( 4 5 )
Mean duration of diabetes in type 1, year 21 6 13 20 6 12 22 6 15
Mean duration of diabetes in type 2, year 9 6 88 6 89 6 9
Mean BMI 28 6 52 7 6 52 8 6 5
Mean A1C level, % 7.4 6 1.3 7.4 6 1.6 7.3 6 1.6
Diabetes complications, n (%)
Neuropathy 25 (10) 11 (9) 14 (11)
Nephropathy 11 (4) 5 (4) 6 (5)
Retinopathy 30 (12) 17 (14) 13 (10)
Foot ulcers 21 (8) 9 (7) 12 (9)
Mean depressive symptoms: CES-D (range 16–60) 28 6 72 9 6 72 8 6 7
Diagnosed with MDD (WHO CIDI), n (%) 146 (57) 71 (57) 75 (58)
Current antidepressive medication use, n ( % ) 2 8( 1 1 ) 1 4( 1 1 ) 1 4( 1 1 )
Mean diabetes-speciﬁc emotional distress: PAID
(range 0–100) 40 6 19 42 6 19 38 6 19
Data are expressed as mean 6 SD, unless stated otherwise. MDD, major depressive disorder. *Intervention
andcontrolgroupdidnotsigniﬁcantlydiffer(P.0.05inallcases)onanyofthesociodemographicorclinical
baseline characteristics.
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on any of the measured baseline charac-
teristics.
Stronger improvements in depressive
symptoms and diabetes distress were
found for completers of the course com-
pared with the control group (both P ,
0.001).
Effect sizes found at the 1-month
follow-up were moderate to high for de-
pressive symptoms (d =0 . 7 0 ,9 5 %C I
0.59–0.82). When calculated for the sub-
group with elevated distress at baseline,
wefoundamoderateeffectsizeofd=0.58
(95%CI0.38–0.78)atthe1-monthfollow-
up (intervention group: n=30, control
group: n=60).
At postassessment and at the 1-month
follow-up,asigniﬁcantlyhigherpercentage
of the intervention group than the control
group could be classiﬁed as “clinically sig-
niﬁcantly improved” (1-month follow-up,
56% vs. 24%; P , 0.001).
CONCLUSIONS—This study is the
ﬁrst to demonstrate the effectiveness of a
Web-based CBT depression intervention
in adults with type 1 or type 2 diabetes.
The intervention was shown to effectively
reduce depressive symptoms and diabetes-
related distress equallyfor individuals with
type 1 and type 2 diabetes. In interpreting
the ﬁndings of this study, we should
acknowledge the strengths and limitations
of the study.
The most important strength of this
study was its strong design: a well-
performed randomized controlled trial.
We were able to attract and enroll a large
number of adult patients with type 1 or
type 2 diabetes who were apparently all
actively looking for treatment, and of
whom 57% had a clinically signiﬁcant
depression.
A major strength of the developed
depression intervention was that it was
based on the proven effective and well-
known CBT Coping with Depression
course developedby Lewinsohn.Another
important strength of the intervention
was that it was made diabetes-sensitive,
by which it complied with the wishes and
needs of diabetic patients.
Regarding the external validity (i.e.,
generalizability) of the study results, we
should acknowledge that we included
patients who were relatively homogenous
demographically. This is likely related to
the use of Internet, which may be less
accessible to elderly, lower educated, and
ethnic minorities. The use of the Inter-
net, however, is rapidly expanding across
society, including among these minori-
ties (21).
Furthermore,ourmethodofrecruiting
participants through a freely accessible
Web site could have led toward a selection
bias by including patients who a priori
believedintheeffectivenessofaWeb-based
intervention and who were highly moti-
vated and proactive. In future studies, we
recommend questionnaires measuring
patients’aprioriconﬁdenceintheeffective-
ness of the therapy, their motivation, and
the reason for participating.
We thought it was unethical to have a
follow-up period longer than 12 weeks
becausepatientsallsufferedfromelevated
depressive symptoms or even a major
depressive disorder and were therefore in
need of treatment.
Because the follow-up assessment
was 1 month after treatment, we cannot
draw between-group conclusions about
long-term effects of the intervention.
Within-group analyses are planned on
data up until 6 months after treatment.
Study attrition was high, in line with
other studies onWeb-basedtherapy (22).
Study attrition was 28% in the control
group compared with 42% in the inter-
vention group, which may be partly
becausethecontrolswereawaitingtreat-
ment and therefore were more moti-
vated.
Althoughusingstate-of-the-artmethods
forimputingmissingdataprovidedus with
the best estimation of real data, also cor-
recting for differences in study attrition
in the intervention and control group, we
should acknowledge that having “true”
data are preferable in any case. Future
studies should seek to use effective strat-
egies to minimize the problem of study
attrition rates.
In contrast to our expectations, the
participants diabetes was relatively well
controlled, with a baseline mean A1C of
7.4%, despite comorbid depression and
highlevelsofdiabetesdistress.Thereason
for this is unclear. One explanation could
be that the patients wishing to join the
study were characterized by a strong
motivation to stay on track with their
diabetes. A subgroup analysis in those
who were poorly controlled also did not
show an effect of the intervention. How-
ever, this may be due to lack of power in
thisanalysis, merely including 27% of the
study population.
Although diabetic patients in the
Netherlands usually visit their treating
physician every 3 months, A1C was not
measured every 3 months. In future
studies we advise that additional A1C
measurements be performed to assure
accuratedataforthepurposeofthestudy.
Moreover, a follow-up of 1 month
may have been too short to capture
meaningful changes in A1C values. De-
creaseofdepressivesymptomsisassumed
to indirectly affect glycemic control by
stresshormonereductionordiabetesself-
care activities. We plan to examine
whether change in depression scores is
associated with changes in self-care activ-
ities in the near future.
Dropout of the intervention is known
to be common in both face-to-face and
Web-based depression treatments, prob-
ablybecausedepressedpatientsoftenlack
energy, have low self-esteem, and low
levelsofoptimism(23,24).Giventhesub-
stantial differences found between ITT
and PP results in our study (with better
results for PP), we may expect that with
morepatientscompletingtheirtreatment,
this would result in higher effect sizes.
Future studies should explore strategies
that can help to lower dropout rates in
depression treatment and thus improve
outcomes, in online as well as in face-to-
face treatment.
In developing our online interven-
tion, we incorporated issues related to
coping with diabetes while preserving the
integrity of CBT. It would be interesting
and relevant to test the superiority of our
intervention to a similar generic Web-
b a s e dd e p r e s s i o ni n t e r v e n t i o ni nd i a b e t i c
patients in a randomized controlled trial.
Considering its delivery by the Inter-
net, our intervention has the potential to
have a large reach and social impact. The
cost-effectiveness of Web-based depres-
sioninterventionshasbeendemonstrated
in the general population (25). Although
the Internet is not yet readily available
around the world, its use is growing fast,
offering a unique opportunity to provide
effective support for diabetes patients in
need of depression treatment.
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